Yanming Biology develops therapeutics centered on innate immune mechanisms and cell pyroptosis regulation. The company operates R&D activities across Beijing and Shanghai and is building dedicated platforms for cell pyroptosis biology and small-molecule immune modulators. Following the announced Pre-B financing, Yanming plans to bolster its Shanghai cell-focused technology platform while advancing multiple Beijing-based small-molecule immunomodulator pipelines toward clinical development. Management said the funds will accelerate preclinical project work and expand its pipeline of potential first-in-class global drug candidates. Existing institutional investors such as Guoxin Fund and Fengrui Capital have increased their investments alongside new lead and participating funds, signaling continued investor support. The articles do not disclose revenues, users, founding year, or valuation.

Total raised

$126M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2026